Clinical Trial Update: Everolimus and Temozolomide in Advanced Gastroenteropancreatic Neuroendocrine Carcinoma (G3) [Phase 2]

View source ↗

Summary

Phase 2 trial investigating everolimus with temozolomide in advanced gastroenteropancreatic neuroendocrine carcinoma (G3) has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Gastroenteropancreatic Neuroendocrine Carcinoma
• Neuroendocrine Carcinoma

Drugs mentioned

• Everolimus (everolimus)
• Temozolomide (Temozolomide)

Snippet

Sponsor: Haukeland University Hospital | Conditions: Neuroendocrine Carcinoma | Phase 2 | Status: COMPLETED